These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9762670)

  • 1. Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis.
    Rieckmann P; Altenhofen B; Riegel A; Kallmann B; Felgenhauer K
    Mult Scler; 1998 Jun; 4(3):178-82. PubMed ID: 9762670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum soluble intercellular adhesion molecule-I in MS: relation to clinical and Gd-MRI activity and to rIFN beta-Ib treatment.
    Trojano M; Avolio C; Ruggieri M; Defazio G; Giuliani F; Paolicelli D; Livrea P
    Mult Scler; 1998 Jun; 4(3):183-7. PubMed ID: 9762671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging.
    Giovannoni G; Lai M; Thorpe J; Kidd D; Chamoun V; Thompson AJ; Miller DH; Feldmann M; Thompson EJ
    Neurology; 1997 Jun; 48(6):1557-65. PubMed ID: 9191766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis.
    Rieckmann P; Altenhofen B; Riegel A; Baudewig J; Felgenhauer K
    Ann Neurol; 1997 Mar; 41(3):326-33. PubMed ID: 9066353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concentration of soluble adhesion molecules (sVCAM-1, sICAM-1 and sL-selectin) in the cerebrospinal fluid and serum of patients with multiple sclerosis and systemic lupus erythematosus with central nervous involvement.
    Baraczka K; Nékám K; Pozsonyi T; Jakab L; Szongoth M; Seszták M
    Neuroimmunomodulation; 2001; 9(1):49-54. PubMed ID: 11435752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b.
    Calabresi PA; Tranquill LR; Dambrosia JM; Stone LA; Maloni H; Bash CN; Frank JA; McFarland HF
    Ann Neurol; 1997 May; 41(5):669-74. PubMed ID: 9153530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS.
    Trojano M; Avolio C; Liuzzi GM; Ruggieri M; Defazio G; Liguori M; Santacroce MP; Paolicelli D; Giuliani F; Riccio P; Livrea P
    Neurology; 1999 Oct; 53(7):1402-8. PubMed ID: 10534242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum endothelial adhesion molecules levels correlate with lesion burden in multiple sclerosis patients treated with interferon beta-1b.
    Dinca LP; Lucas M; Zayas MD; Muñoz MA; Garcia Moreno JM; Navarro G; Gata JM; Solano F; Izquierdo G
    Neurochem Int; 2000 May; 36(6):549-53. PubMed ID: 10762092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial analysis of soluble intercellular adhesion molecule-1 level in relapsing-remitting multiple sclerosis patients during IFN-beta1b treatment.
    Kilinc M; Saatci-Cekirge I; Karabudak R
    J Interferon Cytokine Res; 2003 Mar; 23(3):127-33. PubMed ID: 12716484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell surface bound and soluble adhesion molecules in CSF and blood in multiple sclerosis: correlation with MRI-measures of subclinical disease severity and activity.
    Kraus J; Engelhardt B; Chatzimanolis N; Bauer R; Tofighi J; Kuehne BS; Laske C; Stolz E; Frielinghaus P; Schaefer C; Blaes F; Traupe H; Kaps M; Oschmann P
    J Neuroimmunol; 2002 Jan; 122(1-2):175-85. PubMed ID: 11777557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of interferon beta-1b in patients with secondary progressive multiple sclerosis.
    Rieckmann P; Kruse N; Nagelkerken L; Beckmann K; Miller D; Polman C; Dahlke F; Toyka KV; Hartung HP; Stürzebecher S
    J Neurol; 2005 May; 252(5):526-33. PubMed ID: 15895275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: predominant intrathecal release of vascular cell adhesion molecule-1.
    Droogan AG; McMillan SA; Douglas JP; Hawkins SA
    J Neuroimmunol; 1996 Feb; 64(2):185-91. PubMed ID: 8632061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica.
    Uzawa A; Mori M; Masuda S; Kuwabara S
    Arch Neurol; 2011 Jul; 68(7):913-7. PubMed ID: 21747031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in liver disease, and their changes by treatment with interferon.
    Marui A; Fukuda Y; Koyama Y; Nakano I; Urano F; Yamada M; Hayakawa T
    J Int Med Res; 1996; 24(3):258-65. PubMed ID: 8725986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: correlation with Gd-DTPA magnetic resonance imaging-enhancement and cerebrospinal fluid findings.
    Trojano M; Avolio C; Simone IL; Defazio G; Manzari C; De Robertis F; Calò A; Livrea P
    Neurology; 1996 Dec; 47(6):1535-41. PubMed ID: 8960741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rIFN-beta-1b on serum circulating ICAM-1 in relapsing remitting multiple sclerosis and on the membrane-bound ICAM-1 expression on brain microvascular endothelial cells.
    Trojano M; Defazio G; Avolio C; Paolicelli D; Giuliani F; Giorelli M; Livrea P
    J Neurovirol; 2000 May; 6 Suppl 2():S47-51. PubMed ID: 10871785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-beta-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis.
    Graber J; Zhan M; Ford D; Kursch F; Francis G; Bever C; Panitch H; Calabresi PA; Dhib-Jalbut S
    J Neuroimmunol; 2005 Apr; 161(1-2):169-76. PubMed ID: 15748956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrathecal sICAM-1 production in multiple sclerosis--correlation with triple dose Gd-DTPA MRI enhancement and IgG index.
    Acar G; Idiman F; Kirkali G; Ozakbaş S; Oktay G; Cakmakçi H; Idiman E
    J Neurol; 2005 Feb; 252(2):146-50. PubMed ID: 15729518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
    Scand J Rheumatol; 2009; 38(6):439-44. PubMed ID: 19922018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concentration of soluble adhesion molecules in cerebrospinal fluid and serum of epilepsy patients.
    Luo J; Wang W; Xi Z; Dan C; Wang L; Xiao Z; Wang X
    J Mol Neurosci; 2014 Dec; 54(4):767-73. PubMed ID: 25001004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.